Individualizing liver transplant immunosuppression using a phenotypic personalized medicine platform

Science Translational Medicine

Volumn 8, Issue 333, 2016, Pages

  Zarrinpar, Ali ^a   Lee, Dong Keun ^b   Silva, Aleidy ^c   Datta, Nakul ^a   Kee, Theodore ^c   Eriksen, Calvin ^a   Weigle, Keri ^a   Agopian, Vatche ^a   Kaldas, Fady ^a   Farmer, Douglas ^a   Wang, Sean E ^d   Busuttil, Ronald ^a   Ho, Chih Ming ^a,c   Ho, Dean ^a,b,c,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCLA SCHOOL OF DENTISTRY   (United States)

^c Engineering IV   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PREDNISONE; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

AREA UNDER THE CURVE; ARTICLE; CASE REPORT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; END STAGE LIVER DISEASE; HEALTH CARE QUALITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PHENOTYPE; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; CASE CONTROL STUDY; COMPUTER SIMULATION; DOSE RESPONSE; LIVER TRANSPLANTATION; PHYSICIAN; TREATMENT OUTCOME;

CASE-CONTROL STUDIES; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; PHENOTYPE; PHYSICIANS; PRECISION MEDICINE; PREDNISONE; RETROSPECTIVE STUDIES; TACROLIMUS; TREATMENT OUTCOME;

EID: 84963491185     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aac5954     Document Type: Article

References (34)

1. A. Zarrinpar, R. W. Busuttil, Liver transplantation: Past, present and future. Nat. Rev. Gastroenterol. Hepatol. 10, 434-440 (2013).
2. T. E. Starzl, S. Iwatsuki, B. W. Shaw Jr., R. D. Gordon, C. O. Esquivel, Immunosuppression and other nonsurgical factors in the improved results of liver transplantation. Semin. Liver Dis. 5, 334-343 (1985).
3. S. D. Nimer, A. L. Milewicz, R. E. Champlin, R. W. Busuttil, Cyclosporine bioavailability in heart-lung transplant candidates with cystic fibrosis. Transplantation 49, 821-822 (1990).
4. M. Uesugi, S. Masuda, T. Katsura, F. Oike, Y. Takada, K. Inui, Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenet. Genomics 16, 119-127 (2006).
5. S. Yu, L. Wu, J. Jin, S. Yan, G. Jiang, H. Xie, S. Zheng, Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. Transplantation 81, 46-51 (2006).
6. A. Lampen, U. Christians, F. P. Guengerich, P. B. Watkins, J. C. Kolars, A. Bader, A. K. Gonschior, H. Dralle, I. Hackbarth, K. F. Sewing, Metabolism of the immunosuppressant tacrolimus in the small intestine: Cytochrome P450, drug interactions, and interindividual variability. Drug Metab. Dispos. 23, 1315-1324 (1995).
7. K. S. Lown, R. R. Mayo, A. B. Leichtman, H.-l. Hsiao, D. K. Turgeon, P. Schmiedlin-Ren, M. B. Brown, W. Guo, S. J. Rossi, L. Z. Benet, P. B. Watkins, Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther. 62, 248-260 (1997).
8. European FK506 Multicentre Liver Study Group, Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 344, 423-428 (1994).
9. W. J. Jusko, W. Piekoszewski, G. B. Klintmalm, M. S. Shaefer, M. F. Hebert, A. A. Piergies, C. C. Lee, P. Schechter, Q. A. Mekki, Pharmacokinetics of tacrolimus in liver transplant patients. Clin. Pharmacol. Ther. 57, 281-290 (1995).
10. E. Størset, N. Holford, S. Hennig, T. K. Bergmann, S. Bergan, S. Bremer, A. Åsberg, K. Midtvedt, C. E. Staatz, Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling. Br. J. Clin. Pharmacol. 78, 509-523 (2014).
11. C. Gérard, J. Stocco, A. Hulin, B. Blanchet, C. Verstuyft, F. Durand, F. Conti, C. Duvoux, M. Tod, Determination of the most influential sources of variability in tacrolimus trough blood concentrations in adult liver transplant recipients: A bottom-up approach. AAPS J. 16, 379-391 (2014).
12. N. Han, S. Ha, H.-y. Yun, M. G. Kim, S.-I. Min, J. Ha, J. I. Lee, J. M. Oh, I.-W. Kim, Population pharmacokinetic-pharmacogenetic model of tacrolimus in the early period after kidney transplantation. Basic Clin. Pharmacol. Toxicol. 114, 400-406 (2014).
13. S.-Y. Chen, J.-L. Li, F.-H. Meng, X.-D. Wang, T. Liu, J. Li, L.-S. Liu, Q. Fu, M. Huang, C.-X. Wang, Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism-A prospective, randomized, controlled study. Clin. Transplant. 27, E272-E281 (2013).
14. C. Passey, A. K. Birnbaum, R. C. Brundage, W. S. Oetting, A. K. Israni, P. A. Jacobson, Dosing equation for tacrolimus using genetic variants and clinical factors. Br. J. Clin. Pharmacol. 72, 948-957 (2011).
15. C. Willis, C. E. Staatz, S. E. Tett, Bayesian forecasting and prediction of tacrolimus concentrations in pediatric liver and adult renal transplant recipients. Ther. Drug Monit. 25, 158-166 (2003).
16. K. Benkali, A. Prémaud, N. Picard, J.-P. Rérolle, O. Toupance, G. Hoizey, A. Turcant, F. Villemain, Y. Le Meur, P. Marquet, A. Rousseau, Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients. Clin. Pharmacokinet. 48, 805-816 (2009).
17. S. Loewe, The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 3, 285-290 (1953).
18. T.-C. Chou, P. Talalay, Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22, 27-55 (1984).
19. C. I. Bliss, The calculation of microbial assays. Bacteriol. Rev. 20, 243-258 (1956).
20. P. K. Wong, F. Yu, A. Shahangian, G. Cheng, R. Sun, C.-M. Ho, Closed-loop control of cellular functions using combinatory drugs guided by a stochastic search algorithm. Proc. Natl. Acad. Sci. U.S.A. 105, 5105-5110 (2008).
21. H. Wang, D.-K. Lee, K.-Y. Chen, J.-Y. Chen, K. Zhang, A. Silva, C.-M. Ho, D. Ho, Mechanism-independent optimization of combinatorial nanodiamond and unmodified drug delivery using a phenotypically driven platform technology. ACS Nano 9, 3332-3344 (2015).
22. H. Tsutsui, B. Valamehr, A. Hindoyan, R. Qiao, X. Ding, S. Guo, O. N. Witte, X. Liu, C.-M. Ho, H. Wu, An optimized small molecule inhibitor cocktail supports long-term maintenance of human embryonic stem cells. Nat. Commun. 2, 167 (2011).
23. A. Weiss, X. Ding, J. R. van Beijnum, I. Wong, T. J. Wong, R. H. Berndsen, O. Dormond, M. Dallinga, L. Shen, R. O. Schlingemann, R. Pili, C.-M. Ho, P. J. Dyson, H. van den Bergh, A. W. Griffioen, P. Nowak-Sliwinska, Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer. Angiogenesis 18, 233-244 (2015).
24. M. B. Mohd Abdul Rashid, T. B. Toh, A. Silva, L. Nurrul Abdullah, C.-M. Ho, D. Ho, E. K.-H. Chow, Identification and optimization of combinatorial glucose metabolism inhibitors in hepato-cellular carcinomas. J. Lab. Autom. 20, 423-437 (2015).
25. I. Al-Shyoukh, F. Yu, J. Feng, K. Yan, S. Dubinett, C-M. Ho, J. S. Shamma, R. Sun, Systematic quantitative characterization of cellular responses induced by multiple signals. BMC Syst. Biol. 5, 88 (2011).
26. A. Persidis, Cancer multidrug resistance. Nat. Biotechnol. 17, 94-95 (1999).
27. P. K. Kreeger, Y. Wang, K. M. Haigis, D. A. Lauffenburger, Integration of multiple signaling pathway activities resolves K-RAS/N-RAS mutation paradox in colon epithelial cell response to inflammatory cytokine stimulation. Integr. Biol. 2, 202-208 (2010).
28. H. Li, G. Glusman, H. Hu, J. Caballero, R. Hubley, D. Witherspoon, S. L Guthery, D. E. Mauldin, L. B. Jorde, L. Hood, J. C. Roach, C. D. Huff, Relationship estimation from whole-genome sequence data. PLOS Genet. 10, e1004144 (2014).
29. N. Karamperis, J. V. Povlsen, C. Højskov, J. H. Poulsen, A. R. Pedersen, K. A. Jørgensen, Comparison of the pharmacokinetics of tacrolimus and cyclosporine at equivalent molecular doses. Transplant. Proc. 35, 1314-1318 (2003).
30. J. A. O'Regan, M. Canney, D. M. Connaughton, P. O'Kelly, Y. Williams, G. Collier, D. G. deFreitas, C. M. O'Seaghdha, P. J. Conlon, Tacrolimus trough-level variability predicts long-term allogrfat survival following kidney transplantation. J. Nephrol. 29, 269-276 (2016).
31. S. Gupta, J. D. Mitchell, D.W. Markham, P. P. A. Mammen, P. C. Patel, P. A. Kaiser, P. Stastny, W. S. Ring, J. M. DiMaio, M. H. Drazner, Utility of the Cylex assay in cardiac transplant recipients. J. Heart Lung Transplant. 27, 817-822 (2008).
32. G. E. Malat, C. Culkin, A. Palya, K. Ranganna, M. S. A. Kumar, African American kidney transplantation survival: The ability of immunosuppression to balance the inherent pre- and post-transplant risk factors. Drugs 69, 2045-2062 (2009).
33. L. Ruggeri, M. Capanni, M. Casucci, I. Volpi, A. Tosti, K. Perruccio, E. Urbani, R. S. Negrin, M. F. Martelli, A. Velardi, Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94, 333-339 (1999).
34. J. G. O'Leary, H. Kaneku, B. M. Susskind, L.W. Jennings, M. A. Neri, G. L. Davis, G. B. Klintmalm, P. I. Terasaki. High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection postliver transplant. Am. J. Transplant. 11, 1868-1876 (2011).